scout
Opinion|Videos|August 21, 2024

First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma

Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME